ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

MD Anderson President Ronald DePinho: “Some of the Feedback was Humbling”

March 29, 2013

Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.

November 12, 2004

NCI Shakeup Possibilities Grow; Marc Lippman To Head Lombardi Center; DCT Could Lose CTEP

March 11, 1988

Breast Cancer Coalition Demonstrations Crucial To Obtaining Windfall

October 16, 1992

Text of Peer Review Of Medenica’s Treatment Of Breast Cancer Patient

April 30, 1993

In Brief: Hew Approves Patent Request From U. Arizona; Califano Still Pondering Bioassay Program Fate

September 1, 1978